利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.016 秒)

    Biodegradable implant
    2.
    发明授权
    Biodegradable implant 有权

    公开(公告)号：US10478527B2

    公开(公告)日：2019-11-19

    申请号：US15757475

    申请日：2016-09-05

    申请人： UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

    发明人： Viness Pillay ,  Yahya Essop Choonara ,  Pradeep Kumar ,  Lisa Claire Du Toit ,  Poornima Ramburrun

    IPC分类号： A61L27/48 ,  A61L27/16 ,  A61L27/20 ,  A61L27/52 ,  A61L27/54 ,  A61L27/58 ,  A61L27/56

    摘要： This invention relates to biodegradable implants comprising a hydrogel carrier matrix having dispersed therein a multitude of particles, wherein each of the multitude of particles and/or the hydrogel carrier matrix includes an active pharmaceutical ingredient (API) for the treatment of transected peripheral nerve injuries. Each of the multitude of particles and/or the hydrogel carrier matrix includes pristine polymer particles, preferably the pristine polymer particles may be polymethylmethacrylate polymers and derivatives thereof, preferably poly(methacrylic-co-methyl methacrylate) (PMMA). The spheroidal particles may each be formed from an outer shell including a chitosan (CHT) poly(methacrylic-co-methyl methacrylate) (PMMA) polyelectrolyte complex (CHT-PMMA-PEC) and an inner core including crosslinked chitosan having dispersed therein PMMA nanoparticles.

    Oral pharmaceutical dosage form for the delivery of a peptide and/or protein
    5.
    发明授权
    Oral pharmaceutical dosage form for the delivery of a peptide and/or protein 有权

    公开(公告)号：US10973766B2

    公开(公告)日：2021-04-13

    申请号：US15739809

    申请日：2016-06-27

    申请人： UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

    发明人： Viness Pillay ,  Lisa Claire Du Toit ,  Yahya Essop Choonara ,  Bibi F. Choonara ,  Pradeep Kumar ,  Pierre Pavan Demarco Kondiah

    IPC分类号： A61K9/20 ,  A61K9/14 ,  A61K9/28 ,  A61K9/19

    摘要： The invention relates to an oral polymeric pharmaceutical dosage form which comprises a thermoresponsive eutectic composition which is solid at or about room temperature and fluid at or about body temperature, the eutectic composition mixed together with a crosslinking agent and an active pharmaceutical ingredient (API) to form an API loaded region; and a porous polymeric composition at least partially surrounding the API loaded region to protect the API when the dosage form is in a stomach of the human or animal body, the porous polymeric composition allowing the ingress of water to contact the crosslinking agent thereby facilitating the crosslinking agent to cause crosslinking of the porous polymeric composition, which crosslinked porous polymeric composition allows controlled egress of API via egress of fluid thermoresponsive eutectic composition at the intestine. In a preferred embodiment, the dosage form further comprises a coating there around.

    A Thermoresponsive Hydrogel
    6.
    发明申请
    A Thermoresponsive Hydrogel 审中-公开

    公开(公告)号：US20200054791A1

    公开(公告)日：2020-02-20

    申请号：US16482166

    申请日：2018-01-31

    申请人： University of the Witwatersrand, Johannesburg

    发明人： Yahya Essop Choonara ,  Pierre Pavan Demarco Kondiah ,  Pariksha Jolene Kondiah ,  Pradeep Kumar ,  Lisa Claire Du Toit ,  Thashree Marimuthu ,  Viness Pillay

    IPC分类号： A61L27/52 ,  A61L27/18 ,  A61L27/16 ,  A61L27/26 ,  B01J31/12 ,  C08L67/02 ,  C08L67/04

    摘要： This invention relates to thermoresponsive hydrogels. Particularly, the invention relates to a thermoresponsive hydrogel comprising copolymer polyethylene glycol (PEG)-polycaprolactone (PCL)-polyethylene glycol (PEG) and polypropylene fumerate (PPF). The thermoresponsive hydrogel may further comprise a poloxamer, particularly Pluronic F-127. The invention extends to a method of manufacturing thermoresponsive hydrogels, also extends to an ink for a three dimensional (3D) printer including the thermoresponsive hydrogels. The invention further extends to a thermoresponsive hydrogel for use in the treatment of a bone injury and/or a bone defect, and/or to a method of treating a bone injury and/or a bone defect. The thermoresponsive hydrogels may include dispersed therein an active pharmaceutical ingredient (API), preferably an API falling in the Biopharmaceutics Classification System (BCS) class II, further preferably a statin type drug, most preferably simvastatin.